EGFR × MET Target Pair Landscape — Approved Reference, Multi-Generational Pipeline

1. Executive Snapshot

EGFR × MET is the most mature pair in the Golden Pool — and the only one combining an approved drug, a multi-generational pipeline, and active licensing deals. The anchor asset, amivantamab (JNJ-61186372; RYBREVANT®), is the first approved EGFR×MET bispecific antibody: a fully human IgG1 that blocks EGF/HGF signaling, induces EGFR/MET receptor degradation, and drives Fc-mediated ADCC and macrophage trogocytosis ([J&J MOA](https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-mechanism-of-action)). The FDA label has four NSCLC indication bullets — accelerated ex20ins (2021) → full approval + PAPILLON 1L ex20ins (2024-03) → MARIPOSA 1L EGFRm (2024-08-19) → MARIPOSA-2 post-osimertinib (2024-09); the subcutaneous FASPRO approval (2025-12-17) carries the same four and does not add a fifth indication ([FDA](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer), [FDA SC](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection)). EU SC and 1L approvals are counted separately; MARIPOSA final OS was positive ([NEJM 2025](https://www.jnj.com/media-center/press-releases/data-published-in-the-new-england-journal-of-medicine-demonstrate-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-is-re-setting-survival-expectations-in-first-line-egfr-mutated-lung-cancer)).

The rationale is textbook: EGFR is the driver oncogene; MET amplification/HGF overexpression is the best-characterized bypass route to EGFR TKIs, ~15–20% of osimertinib resistance ([Front Oncol 2024](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1447678/full)). One molecule covers primary driver plus acquired resistance. The same biology explains the pair's failures — single-target MET (onartuzumab, emibetuzumab) and the earlier EGFR×MET BsAb LY3164530 all failed: format and engineering, not target choice alone, decide success. Draft score: 91/100 → Golden (GP-05 ledger).

2. Asset Landscape

Approved

Clinical (Phase 1–2)

Discontinued (control set)

Adjacent validation: telisotuzumab vedotin (EMRELIS™), AbbVie's c-MET ADC, won FDA accelerated approval 2025-05-14 in high c-MET-overexpressing NSCLC — confirming MET as a druggable surface target ([CURE](https://www.curetoday.com/view/fda-approves-emrelis-in-previously-treated-advanced-nsclc)).

The generational shift "naked BsAb → BsAb ADC" is underway (AZD9592, DM005, Novatim NDC); each new program needs EGFR/MET ECD reagents, dual-binding characterization, cyno cross-reactivity, and endocytosis/effect-function assays — durable, multi-generational tool demand.

3. Companies

• J&J / Janssen — amivantamab owner; A+L (amivantamab+lazertinib) with Yuhan (2018, up to $1.25B, [BioSpace](https://www.biospace.com/janssen-inks-deal-with-korea-s-yuhan-for-nsclc-drug-valued-at-up-to-1-25-billion)); FASPRO 2025-12. Commercial and data anchor of the pair.
• Merus N.V. — Biclonics platform; MCLA-129 China rights to Betta Pharma (2018-12-10, $1.0M upfront + cost sharing, [Merus 10-K](https://ir.merus.nl/static-files/4f87e1ed-da53-4a0e-b7ed-9e90161b559e)); Betta combining with ensartinib.
• AstraZeneca — AZD9592: a big-pharma direct bet on the BsAb-ADC modality.
• EpimAb Biotherapeutics — FIT-Ig platform, EMB-01; cumulative platform out-licensing >$2.1B (2026); Almirall's first FIT-Ig CTA 2026-02.
• Eli Lilly — the pair's negative-history provider (LY3164530, emibetuzumab): first-mover ≠ success.
• Doma Biopharmaceutical (Suzhou) — DM005 BsAb ADC; consecutive ASCO 2025/2026 data.
• Novatim Immune + Radiance Biopharma — nanobody BsAb ADC; 2025 ex-China license (up to $1.165B).
• AbbVie (adjacent) — EMRELIS approval de-risks MET as a target.
• Yuhan (Korea) — lazertinib originator; revenue share on A+L sales.

4. Clinical & Deal Timeline

5. Risks & Failures

• VTE: 37% in the MARIPOSA A+L arm vs 9% with osimertinib — flagged in the label/DailyMed, the [EMA PI](https://www.ema.europa.eu/en/documents/product-information-tracked-changes/rybrevant-epar-product-information-tracked-changes_en.docx) and J&J's [VTE safety page](https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-venous-thromboembolism-vte); routine anticoagulation is a clinical expectation.
• IRR ~66–67% in CHRYSALIS — step-dosing and premedication required ([RxList](https://www.rxlist.com/rybrevant-drug.htm)).
• 49% serious adverse events with IV amivantamab+lazertinib ([DailyMed FASPRO](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69&type=display)); Grade ≥3 AEs 75% vs 43% in MARIPOSA ([Curr Oncol Rep 2025](https://link.springer.com/article/10.1007/s11912-025-01723-w)). Skin toxicity, ILD/pneumonitis (~3–4%) and ocular toxicity are warning-level items.
• MARIPOSA-2: second interim OS analysis not statistically significant (ESMO 2024); the chemo combination adds hematologic toxicity.
• Single-target MET blockade failed twice: onartuzumab (Ph3, 2014) and emibetuzumab (Ph2, no PFS benefit) — the pair's central lesson: dual targeting, not MET alone.
• LY3164530 terminated in Ph1 (2018): dose-limiting toxicity, no RP2D, no objective responses — dual targeting per se is insufficient; format, affinity and dosing are decisive.
• Label constraint: all approved indications are EGFR-mutant NSCLC; MET amplification is the mechanism, not an approved biomarker — MET IHC/FISH thresholds remain unstandardized.

6. Discovery Questions

• Resistance frequency & dynamics: real-world share of MET amplification in osimertinib resistance (~15–20%); can EGFR×MET force escape toward MET-independent routes (C797S, HER2, KRAS)?
• Mechanism attribution: does amivantamab's benefit derive mainly from signaling blockade, receptor degradation, or ADCC/trogocytosis — and does the weighting differ between MET-amp and non-MET patients?
• Format–activity relationship: why did the 1:1 LY3164530 fail while amivantamab succeeded; what is the optimal design for tetravalent (EMB-01) vs BsAb-ADC (AZD9592/DM005) at varying EGFR/MET density ratios?
• Biomarkers: predictive value of MET IHC (clone/threshold) and FISH; feasibility of circulating sMET / ctDNA MET-amplification monitoring.
• Indication expansion & sequencing: CRC (EMB-01 subgroup), gastric/HNSCC, MET-amp pan-tumor; ordering of A+L vs A+chemo vs BsAb-ADC vs checkpoint combinations.

7. Why This Matters Now

This is the only "approved + multi-generational pipeline + active deals" pair in the pool — a template asset for LoFly's tool, service, and intelligence lines (GP-05 analyst note; 91/100 Golden). The underlying biology is the highest-frequency, best-validated EGFR-TKI resistance route — MET amplification in ~15–20% of osimertinib resistance — so reagent and assay demand persists across generations, from naked BsAb to BsAb ADC. Yet it also carries the heaviest safety signal in the pool (VTE 37% vs 9%, IRR ~66–67%, 49% serious AEs), leaving competitive space open for safer formats, biomarker-guided selection, and prophylaxis strategies. The balanced read: most mature pair, most cautionary profile — and therefore the strongest case for intelligence-led differentiation rather than me-too development.

8. Sources

FDA labels & approvals

• [FDA: A+L 1L approval (MARIPOSA), 2024-08-19](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer)
• [FDA: RYBREVANT FASPRO SC approval, 2025-12-17](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection)
• [DailyMed label: VTE 37% vs 9%; serious AEs 49%](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9e58b045-e352-4f62-99bf-77fae1bebc69&type=display)
• [EMA RYBREVANT product information](https://www.ema.europa.eu/en/documents/product-information-tracked-changes/rybrevant-epar-product-information-tracked-changes_en.docx)
• [J&J MOA](https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-mechanism-of-action) · [J&J VTE safety](https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-venous-thromboembolism-vte) · [RxList: IRR ~66–67%](https://www.rxlist.com/rybrevant-drug.htm)

Key trials & data

• [J&J PR: PAPILLON, 2024-03-01](https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations)
• [NEJM 2025: MARIPOSA final OS](https://www.jnj.com/media-center/press-releases/data-published-in-the-new-england-journal-of-medicine-demonstrate-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-is-re-setting-survival-expectations-in-first-line-egfr-mutated-lung-cancer) · [ASCO Post summary](https://ascopost.com/news/september-2025/amivantamab-plus-lazertinib-vs-osimertinib-in-egfr-mutated-advanced-nsclc/)
• [Grade ≥3 AEs 75% vs 43% (Curr Oncol Rep 2025)](https://link.springer.com/article/10.1007/s11912-025-01723-w)
• [MET amplification in osimertinib resistance (Front Oncol 2024)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1447678/full)
• [MARIPOSA-2 approval note (Pharmacy Times)](https://www.pharmacytimes.com/view/fda-approves-amivantamab-vmjw-for-nsclc-with-egfr-exon-19-deletions-or-l858r-mutations)

Pipeline & deals

• [MCLA-129 global Ph1/2 NCT04868877](https://clinicaltrials.gov/study/NCT04868877) · [Merus 10-K: Betta license](https://ir.merus.nl/static-files/4f87e1ed-da53-4a0e-b7ed-9e90161b559e) · [Betta China NCT06885840](https://ichgcp.net/clinical-trials-registry/NCT06885840)
• [AZD9592 Ph1 NCT05647122](https://www.trialfetch.com/trial_match/view_trial/NCT05647122/)
• [EMB-01 Ph1/2 NCT03797391](https://clinicaltrials.gov/study/NCT03797391) · [EMB-01 CRC subgroup (ASCO 2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.118)
• [DM005 Ph1 NCT06515990](https://ichgcp.net/clinical-trials-registry/NCT06515990) · [ASCO 2025 e15010](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e15010)
• [Radiance–Novatim ex-China license (up to $1.165B)](https://www.pharmexec.com/view/radiance-biopharma-agrees-exclusive-license-novatim-immune-therapeutics-c-met-egrf-targeted-nano-antibody)
• [Yuhan–Janssen lazertinib deal (up to $1.25B)](https://www.biospace.com/janssen-inks-deal-with-korea-s-yuhan-for-nsclc-drug-valued-at-up-to-1-25-billion)

Failures & adjacent validation

• [LY3164530 Ph1 termination](https://pubmed.ncbi.nlm.nih.gov/29926131/)
• [Emibetuzumab Ph2 (ASCO 2017 #9019)](https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9019)
• [Onartuzumab Ph3 failure (BioWorld)](https://www.bioworld.com/articles/396396-genentech-s-onartuzumab-fails-in-phase-iii-trial-for-non-small-cell-lung-cancer)
• [EMRELIS accelerated approval (CURE)](https://www.curetoday.com/view/fda-approves-emrelis-in-previously-treated-advanced-nsclc)

*Evidence grades: A/B only; all load-bearing facts from gp-master GP-05 ledger (evidence_cutoff 2026-08-19). Draft pending founder Grade A/B review.*

Research tools this landscape implies: packaged EGFR/MET ECD reagents (human + cyno, His/AVI-biotin — human EGFR/MET ECD are commercialized, e.g. [Sino Biological](https://www.sinobiological.com/recombinant-proteins/human-c-met-10692-h27h-b), [human EGFR](https://cn.sinobiological.com/recombinant-proteins/human-egfr-10001-h27h-b), [cyno EGFR](https://kr.sinobiological.com/recombinant-proteins/cynomolgus-egfr-90285-c08h-b), [cyno MET](https://kr.acrobiosystems.com/products/protein/hgf-r-cynomolgus-met-c82e3)); a standardized cyno cross-reactivity panel; and a dual-binding/trogocytosis service gap — dual-antigen co-engagement assays (BLI/SPR/bridging ELISA, e.g. [Octet example](https://pmc.ncbi.nlm.nih.gov/articles/PMC10877975/)) plus ADCC/trogocytosis/endocytosis bioassays remain only half-commercialized.